EVIDENCE LIBRARY
Ketamine Stress Pilot’s Primary Comparison Against Midazolam Did Not Reach Statistical Significance
A twenty-four-person pilot found a numerical anxiety difference after a laboratory stressor. Its exploratory biomarker analysis did not turn the primary result into demonstrated protection.
A twenty-four-person pilot found a numerical anxiety difference after a laboratory stressor. Its exploratory biomarker analysis did not turn the primary result into demonstrated protection.
The planned comparison
Healthy adults received ketamine or midazolam one week before a laboratory stress test. Midazolam served as an active control. The primary anxiety comparison favored ketamine numerically but had p=0.06.
There was no overall group effect on salivary cortisol or alpha-amylase change. A secondary analysis excluding one participant found an alpha-amylase difference, without formal multiple-testing adjustment.
A pilot remains uncertain
Small groups permit imprecise estimates and missed effects. An exploratory subgroup result needs to retain its selection and multiplicity limitations. The laboratory stress response is not a diagnosis or prevention outcome for post-traumatic stress disorder.
The study does not establish midazolam as a stress-prevention treatment, and its active-control role should not be confused with treatment of a clinical anxiety disorder. The paper supports further research while leaving long-term resilience, disease prevention, and the meaning of the biomarker pattern unresolved.
Source paper
Original analysis of the supplied journal article, identified as PMC9813787.